环球医疗是一家央企控股的医疗健康产业集团。截至报告期末，集团旗下运营了68家综合及专科医疗机 构；此外，集团业务还涉及开展医疗设备全周期管理、智慧医康养等健康科技业务；以及客户提供以融 资租赁为核心的综合金融解决方案。 此外，上半年,公司专科医疗业务发展基础不断夯实。眼科以并购山东中医药大学附属眼科医院为起点, 体系内综合医疗机构眼科专科转型发展进程全面提速,北京中兴医院眼科医院即将正式营业;与北京清华 长庚医院达成肿瘤专科联盟合作意向,并战略推动全球创新技术引入与布局;推进烟台海港医院建设三级 中西医结合医院,成为"山东中医药大学临床教学实践基地"及"山东中医药大学第二附属医院医联体单 位",落地1家国家级名老中医工作室,并与成都中医药大学签署战略合作协议等。 财报还显示，环球医疗以通用环球医疗技术服务(天津)有限公司为产业平台，为医院客户提供以"管"为 核心的"管、采、养、用、修"全生命周期管家式服务，有效提升医疗设备运营效率和管理水平，延长医 疗设备使用寿命，助力医院降本、提质、增效。2025年上半年，集团设备全周期管理业务持续拓展，经 营业绩稳步提升，贡献报表收入4.18亿元，较上年同期增长58.7% ...

Core Viewpoint - Recently, Zhonghong Medical (300981.SZ) has gained attention in the capital market due to its subsidiary obtaining three medical device registration certificates and its plan to acquire a Southeast Asian glove manufacturer for 6.97 million RMB [1][3]. Group 1: Medical Device Registration - On July 8, Zhonghong Medical announced that its subsidiary, Jiangxi Kelong Medical Device Manufacturing Co., Ltd., obtained two medical device registration certificates from the Jiangxi Provincial Drug Administration and one from the National Medical Products Administration [1]. - The registration certificates are for the continuation of existing products, with effective periods extended from original expiration dates in 2025 and 2026 to new dates in 2030 and 2031 [2]. - The extension of these certificates ensures the continued sales of products in the fields of disposable sterile care packages, disposable sterile syringes (with needles), and medical dressings, enhancing the company's competitive edge and market expansion capabilities [2]. Group 2: Acquisition of SEA3 Company - Zhonghong Medical plans to acquire 75% of the Southeast Asian SEA3 company for a total cash consideration of 6.97 million RMB, with Zhonghong Hong Kong acquiring 52.5% and Hengbao International acquiring 22.5% [3][5]. - Following the acquisition, Zhonghong Hong Kong and Hengbao International will inject additional capital into SEA3, totaling approximately 7.57 million RMB [5]. - SEA3 specializes in the production and sale of medical-grade gloves and holds various international certifications, including EU ISO13485, CE, and US FDA 510(k) [6]. Group 3: Financial Performance - As of March 31, 2025, SEA3 reported total assets of 136 million RMB and a net asset deficit of 492,400 RMB, with revenues of 6.56 million RMB and a net loss of 372,210 RMB for the first quarter of 2025 [6]. - Zhonghong Medical's performance in Q1 2025 showed revenues of 629 million RMB, a year-on-year increase of 15.45%, and a net profit of 18.92 million RMB, reflecting a significant year-on-year growth of 1369.95% [7].

Core Viewpoint - The healthcare industry in Erqi District is experiencing significant growth and innovation, with a focus on building a comprehensive ecosystem for biocell technology and cancer treatment solutions [1][3][6]. Group 1: Industry Development Strategy - Erqi District has established a "Six Medicine" development strategy, focusing on medical, healthcare, pharmaceuticals, medical aesthetics, health management, and medical psychology [3]. - The district is creating a "medical health industry development axis" along University Road, integrating sports health and cultural tourism [3]. - A dedicated task force has been formed by district leaders to enhance the healthcare industry, resulting in the issuance of measures to promote high-quality development [3]. Group 2: Infrastructure and Investment - The district is developing high-quality health industry parks, such as the He Medical Health Service and Medical Technology Innovation Park, leveraging local hospital resources [5]. - The Eurasia land urban renewal project plans to invest 690 million yuan in constructing a comprehensive park for medical research, health services, and industrial internet [5]. - The establishment of the ZH Medical Instrument High-end Intelligent Manufacturing Industrial Park has successfully attracted over 300 companies within a year [5]. Group 3: Innovation and Talent Development - Erqi District is collaborating with local universities to supply research and skilled talent to the healthcare industry, having established 24 provincial-level medical key laboratories and 104 municipal-level laboratories [6]. - The newly built Saiosibo International CGT Research Center features a 2,000 square meter core laboratory and is equipped with an internationally certified GMP production workshop and AI-assisted R&D systems [6]. - The district aims to continue enhancing the "Six Medicine" initiative, promoting the healthcare industry towards high-end, intelligent, and clustered development [6].